Compare Adaptive Biotechnologies Corp (ADPT) vs Fox Corp Class B (FOX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Fox Corp Class B — how do they compare? Adaptive Biotechnologies Corp trades at $25.36 (market cap $4.04B), while Fox Corp Class B trades at $54.96 (market cap $24.58B). The key difference: Fox Corp Class B is far larger — about 6.1× Adaptive Biotechnologies Corp's market cap, and Fox Corp Class B pays a 1.05% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | FOX | |
|---|---|---|
Market Cap | $4.04B | $24.58B |
Sector | Health | Media |
52-Week High | $25.45 | $67.76 |
52-Week Low | $12.30 | $44.39 |
Enterprise Value | $4.10B | $27.94B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
FOX trades at $56.33, down 1.23% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent earnings beats and strong 2025 results, including $16.3B revenue and $2.26B net income, support a P/E of 14.41. Positive news includes Tubi's partnership with Gracenote for CTV advertising growth (PRNewswire, Aug 12, 2026).
The outlook is positive with robust ad momentum and digital expansion, though risks include cyclical advertising exposure and high RSI suggesting near-term pullback potential. Analyst consensus leans neutral with 42.86% buy ratings, indicating cautious optimism for long-term holders amid competitive media pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →
